I first wrote about Organon in March 2025 based on the FY2024 10-K. A lot has changed since then.
Organon (OGN) is a global healthcare company headquartered in Jersey City, New Jersey, generating $6.2 billion in revenue across three segments: Women’s Health, Biosimilars, and Established Brands. Merck spun the company off in June 2021, bundling together its older off-patent drug portfolio, its women’s health franchise, and a developing biosimilars business. As part of the separation, Merck loaded Organon with roughly $9 billion in debt. Four years later, the debt stands at $8.6 billion, the founding CEO was forced out over an inventory manipulation scandal, the stock has lost more than 75% of its value since the IPO, and the company faces a $3.6 billion debt maturity wall in 2028. The market cap is $1.6 billion. The enterprise value is $9.8 billion. The central question for equity holders is whether Organon’s growth assets can generate enough cash to service the debt and eventually deleverage, or whether the equity gets slowly crushed between declining legacy revenue and rising interest costs.
How Organon Makes Money
Organon operates three reporting segments. Each has a distinct role in the portfolio.
Women’s Health ($1.75 billion, 28% of revenue)
The anchor product is Nexplanon, a subdermal contraceptive implant that generated $921 million in FY2025 revenue. Nexplanon is a small radiopaque rod inserted under the skin of the upper arm by a trained healthcare provider. It releases etonogestrel over an extended period to prevent pregnancy. The FDA approved a 5-year duration of use in January 2026, extending the prior 3-year label. That approval came with a new REMS program and grants Organon a period of clinical investigation exclusivity, which supplements the existing patent protection (rod patents expire 2027, applicator patents 2030).
The rest of Women’s Health includes the fertility franchise (Follistim AQ, Elonva, Ganirelix Acetate) at $365 million, NuvaRing at $91 million (declining under generic pressure), and several smaller products. Organon divested its Jada postpartum hemorrhage system to Laborie Medical Technologies in January 2026 for up to $465 million ($440 million upfront), using the proceeds to pay down debt.
In February 2026, Organon licensed global rights to Miudella, a hormone-free copper intrauterine device, from Sebela Pharmaceuticals. The deal includes $27.5 million upfront and up to $505 million in milestone payments. Miudella fills a gap in Organon’s contraception portfolio by offering a non-hormonal option, an area seeing growing consumer demand.
Biosimilars ($691 million, 11% of revenue)
Biosimilars is the fastest-growing segment. The standout is Hadlima, a biosimilar to AbbVie’s Humira, which generated $228 million in FY2025, up 60% year-over-year. Organon does not develop these products in-house. The company partners with Samsung Bioepis and Shanghai Henlius for development and manufacturing, then handles commercialization. The economics involve a gross profit split, typically 50/50 with Samsung Bioepis (65/35 in Brazil).
The current marketed portfolio includes eight biosimilars spanning immunology and oncology:
| Product | Reference Drug | Key Markets |
|---|---|---|
| Hadlima | Humira (adalimumab) | US, global |
| Renflexis | Remicade (infliximab) | US, global |
| Brenzys | Enbrel (etanercept) | Ex-US |
| Ontruzant | Herceptin (trastuzumab) | US, EU, global |
| Aybintio | Avastin (bevacizumab) | EU, Canada |
| Bildyos | Prolia (denosumab) | US, global |
| Bilprevda | Xgeva (denosumab) | US, global |
| Poherdy | Perjeta (pertuzumab) | US (approved Nov 2025, launch planned ~late 2028) |
Poherdy, the pertuzumab biosimilar, is notable because the FDA granted it interchangeability status, making it the first and only pertuzumab biosimilar approved in the US. US launch timing will depend on patent litigation and settlements with Roche/Genentech.
Established Brands ($3.69 billion, 59% of revenue)
This is the largest segment by revenue and the one in structural decline. It consists of dozens of off-patent legacy Merck brands sold across 140+ countries. The segment is heavily international: 92% of Established Brands revenue comes from outside the United States.
The major therapeutic areas include:
| Category | Key Brands | FY2025 Revenue |
|---|---|---|
| Cardiovascular | Zetia/Ezetrol, Vytorin/Inegy, Atozet, Cozaar, Hyzaar | $1.1 billion |
| Respiratory | Singulair, Dulera/Zenhale, Asmanex, Nasonex, Clarinex/Aerius | $842 million |
| Pain, Bone, Dermatology | Arcoxia, Fosamax, Diprospan, Vtama, Diprosone, Elocon | $987 million |
| Other | Emgality (migraine), Proscar, Propecia | $761 million |
Two products within this segment deserve special attention because they are growing against the overall trend of decline:
Vtama (tapinarof cream) generated $128 million in its first full year under Organon’s ownership. Organon acquired Vtama through its purchase of Dermavant Sciences in October 2024 for $1.2 billion. Vtama is FDA-approved for both plaque psoriasis and atopic dermatitis (in adults and children 2 years and older), with the atopic dermatitis approval granted in December 2024. Patent protection runs through 2036. This is Organon’s best shot at a new growth franchise, and the international launch is planned starting in 2026.
Emgality (galcanezumab), a CGRP inhibitor for migraine prevention, generated $174 million, up 63% year-over-year. Organon holds distribution rights via a partnership with Eli Lilly, earning a profit split on commercial sales. This is pure commercial execution on someone else’s molecule, which is exactly the model Organon does best.
The structural headwind in Established Brands is LOE. In FY2025, Organon estimated $197 million in revenue losses from LOE impacts, primarily from Atozet patent expiration in certain markets and generic competition on other cardiovascular products. China’s VBP program and Japan’s biennial drug pricing revisions create additional downward pressure on pricing.
The Global Distribution Machine
What makes Organon unusual is the thing that is hardest to see in the financials. The company operates a pharmaceutical distribution network spanning more than 140 countries, with 74% of total revenue generated outside the United States. This infrastructure was built over decades inside Merck, and replicating it would cost years and billions.
Organon operates six owned manufacturing facilities (in Brazil, Belgium, Indonesia, the Netherlands, and two in the US) plus a network of contract manufacturers. The company maintains direct commercial operations in dozens of countries where many mid-size pharma companies would rely on distribution partners.
The business model is built around this network. Organon acquires or licenses products from other companies (Vtama from Dermavant, Emgality from Lilly, biosimilars from Samsung Bioepis and Henlius, Miudella from Sebela) and then pushes them through its global commercial engine. The company does not spend heavily on early-stage R&D. Total R&D spending in FY2025 was $353 million, with $271 million of that going to in-process research and development charges related to the Dermavant acquisition and Miudella licensing. Underlying R&D spend is closer to $80-100 million, which is modest for a $6 billion revenue company.
This “acquire and distribute” model has clear advantages: lower R&D risk, faster time to revenue from new assets, and leverage on the existing global infrastructure. The disadvantage is that Organon depends on a continuous supply of externally sourced products, and it competes for those assets against larger, better-capitalized buyers.
Financial Profile
Income Statement
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $6,216M | $6,403M | $6,263M |
| Cost of Sales | $2,903M | $2,688M | $2,515M |
| Gross Profit | $3,313M | $3,715M | $3,748M |
| Gross Margin | 53.3% | 58.0% | 59.8% |
| SG&A | $1,700M | $1,573M | $1,618M |
| R&D | $353M | $371M | $511M |
| Restructuring | $95M | $11M | $50M |
| Goodwill Impairment | $301M | $0 | $0 |
| Operating Income | $824M | $1,374M | $1,257M |
| Interest Expense | $504M | $505M | $494M |
| Net Income | $187M | $864M | $1,023M |
| Diluted EPS | $0.72 | $3.33 | $3.99 |
| Adjusted EBITDA | $1,910M | $2,034M | $1,913M |
Several things stand out. Revenue declined 3% in FY2025. Gross margin compressed nearly 500 basis points over two years, driven by manufacturing network optimization costs, unfavorable product mix, and higher input costs. The $301 million goodwill impairment was tied to the US reporting unit, signaling that management’s own projections for US operations have deteriorated. The $95 million restructuring charge reflects a 6% headcount reduction announced in 2025.
Interest expense consumed $504 million in FY2025, which is 61% of operating income and 8.1% of revenue. For perspective, Organon spends more on interest than it does on R&D, SG&A-related selling costs, or any single product franchise except Nexplanon and the cardiovascular portfolio.
Cash Flow
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Cash Flow | $700M | $939M | $799M |
| Capital Expenditures | ($162M) | ($175M) | ($251M) |
| Free Cash Flow | $538M | $764M | $548M |
| Dividends Paid | ($198M) | ($290M) | ($290M) |
| Debt Repayment | ($530M) | ($323M) | ($125M) |
Free cash flow generation is the single most important number for Organon. At $538 million in FY2025, the company generates enough cash to service its debt and maintain operations, but not enough to rapidly deleverage. The dividend was cut from $1.12 per share to $0.34 per share in 2025, and then further to $0.08 per share annualized (a $0.02 quarterly dividend declared in February 2026). That frees up roughly $270 million per year versus the prior payout level.
Balance Sheet and Debt Stack
Total debt at year-end 2025 was $8,644 million. Cash on hand was $574 million. Net debt was $8,070 million, which represents a net leverage ratio of 4.2x adjusted EBITDA.
The full debt stack:
| Instrument | Amount | Rate | Maturity |
|---|---|---|---|
| US Dollar Term Loan B | $1,543M | SOFR + 2.25% | 2031 |
| Euro Term Loan B | €717M (~$843M) | EURIBOR + 2.75% | 2031 |
| 4.125% Senior Secured Notes | $2,100M | 4.125% | 2028 |
| 2.875% Euro Senior Secured Notes | €1,250M (~$1,470M) | 2.875% | 2028 |
| 5.125% Senior Unsecured Notes | $1,582M | 5.125% | 2031 |
| 6.750% Senior Secured Notes | $500M | 6.750% | 2034 |
| 7.875% Senior Unsecured Notes | $500M | 7.875% | 2034 |
| RIPSA (Vtama royalty financing) | $179M | Variable | Ongoing |
The weighted average cost of debt is around 4.9%. The critical observation is that $3.6 billion matures in 2028: the $2.1 billion 4.125% secured notes and the €1.25 billion 2.875% euro secured notes. These were priced at historically low rates during the spinoff. Refinancing them in 2027 or 2028, with the company carrying material weaknesses in ICFR and an open SEC investigation, will almost certainly come at a higher rate. Every 100 basis points of increase on $3.6 billion adds $36 million in annual interest expense.
Organon has a $1.3 billion revolving credit facility that was undrawn at year-end. The company also repurchased $419 million of its 2031 unsecured notes at a discount during 2025, booking a $69 million gain. That was smart capital allocation given the bonds were trading below par.
The Governance Problem
In October 2025, Organon’s Audit Committee disclosed findings from an independent investigation into US wholesaler sales practices. The investigation found that former CEO Kevin Ali had pressured two US wholesalers to purchase excess Nexplanon inventory in order to meet revenue guidance. The conduct occurred in Q4 2022, Q3-Q4 2024, and Q1-Q3 2025.
The specifics: management waived inventory management fee metrics so wholesalers would not be penalized for holding excess stock, effectively overriding the controls designed to prevent channel stuffing. The incremental revenue impact was small in context, less than 1% of annual revenue and less than 2% of quarterly revenue in any affected period. But the implications were serious.
Ali and the Head of US Commercial resigned. The Board appointed Joseph Morrissey, formerly EVP of Manufacturing Operations, as Interim CEO. Carrie Cox, a board member, became Executive Chair. The search for a permanent CEO is ongoing.
PwC issued an adverse opinion on ICFR in the FY2025 10-K, citing material weaknesses related to the tone at the top and the override of controls. Importantly, PwC issued a clean opinion on the financial statements themselves, finding no material misstatement. No restatement was required.
The consequences are still unfolding. Organon voluntarily reported the findings to the SEC in October 2025, and an SEC investigation is open. Two securities class action lawsuits and two shareholder derivative suits have been filed. The company is also cooperating with the DOJ.
For investors, the governance problem does three things. First, it injects uncertainty around potential fines and legal costs. Second, it will increase the cost of the 2028 refinancing. Third, it leaves the company without a permanent CEO during a period that requires active portfolio management and debt restructuring.
The Fosamax Litigation
Organon inherited ongoing litigation from Merck related to Fosamax (alendronate sodium), a bisphosphonate used for osteoporosis. Plaintiffs allege that Fosamax causes atypical femoral fractures. There are roughly 2,266 cases pending across federal courts, New Jersey state courts, and California state courts.
A New Jersey settlement was agreed to in the fourth quarter of 2025 on terms the company describes as not material. However, federal and California cases remain active. The preemption defense, which argued that federal drug labeling rules preempted state failure-to-warn claims, was rejected by the Third Circuit. The Supreme Court denied certiorari, leaving the Third Circuit ruling in place and opening Organon to broader liability.
The 10-K does not disclose a specific reserve amount for Fosamax litigation. This is a tail risk that could produce a meaningful charge but is difficult to quantify from public filings alone.
Nexplanon: The Crown Jewel Under Threat
Nexplanon deserves its own section because it generates $921 million in revenue, carries high margins, and faces a direct generic challenge.
In February 2025, Xiromed filed an ANDA seeking to market a generic version of Nexplanon. Organon sued for patent infringement, triggering a 30-month stay on FDA approval under Hatch-Waxman. The stay runs until roughly mid-2027.
Organon’s defense rests on several layers:
- Rod patents (etonogestrel implant composition): expire 2027
- Applicator patents (the proprietary insertion device): expire 2030
- 5-year label: The January 2026 approval of the 5-year duration creates clinical investigation exclusivity under the FDA’s regulations. A generic referencing Nexplanon would only be able to claim 3-year duration unless the applicant conducts its own clinical studies
- REMS program: The new REMS requires a specific training and certification program for inserters and is tied to Organon’s controlled distribution system
The combination of these protections makes it harder for a generic to replicate the full commercial proposition, but not impossible. A generic Nexplanon with a 3-year label at a lower price would still capture some market share, particularly in price-sensitive channels. The timing suggests generic competition could arrive as early as late 2027 or 2028, which overlaps uncomfortably with the debt maturity wall.
2026 Guidance and Forward Outlook
Management guided for FY2026 revenue of $6.1 to $6.3 billion and adjusted EBITDA of $1.85 to $1.95 billion. That is roughly flat with FY2025. The company expects gross margin to deteriorate by another 75 to 100 basis points due to continued manufacturing optimization costs and product mix shifts.
The implied message from flat guidance is that growth in Biosimilars, Vtama, and Emgality is expected to roughly offset continued erosion in Established Brands and the loss of Jada revenue following the divestiture.
Valuation
Method 1: EV/EBITDA
Organon’s FY2025 adjusted EBITDA was $1.91 billion. Peer companies in the generic/established pharma space (Viatris, Teva, Bausch Health) trade at 5x to 7x EV/EBITDA, though most of those have better governance profiles and less concentrated debt maturities.
| Scenario | Multiple | Enterprise Value | Less Net Debt | Equity Value | Per Share |
|---|---|---|---|---|---|
| Bear | 4.5x | $8.6B | ($8.1B) | $0.5B | $1.92 |
| Base | 5.5x | $10.5B | ($8.1B) | $2.4B | $9.23 |
| Bull | 6.5x | $12.4B | ($8.1B) | $4.3B | $16.54 |
The bear case at 4.5x barely covers the debt. This is the scenario where refinancing goes badly, Nexplanon faces early generic entry, and the SEC investigation produces a large fine.
Method 2: Discounted Cash Flow (Simplified)
Assumptions for the base case: - Normalized free cash flow: $600M (between FY2025’s $538M and FY2024’s $764M, reflecting dividend savings) - FCF growth: -2% annually (established brand erosion partially offset by biosimilar/Vtama growth) - Discount rate: 12% (reflecting high leverage and governance risk) - Terminal multiple: 5x FCF in year 10
| Year | FCF |
|---|---|
| 1 | $600M |
| 2 | $588M |
| 3 | $576M |
| 4 | $565M |
| 5 | $553M |
| 6 | $542M |
| 7 | $532M |
| 8 | $521M |
| 9 | $510M |
| 10 | $500M |
| Terminal value (5x Year 10 FCF) | $2,501M |
Present value of cash flows: ~$3.2 billion. Present value of terminal value: ~$805 million. Total enterprise value: ~$4.0 billion.
Less net debt of $8.1 billion, this DCF produces negative equity value. That result reflects the reality that at a 12% discount rate, a slowly declining cash flow stream does not cover the debt. This is the mathematical expression of why the stock trades where it trades.
To get positive equity value in the DCF, you need either: (a) FCF growth to turn positive (Vtama becomes a blockbuster, biosimilars ramp faster than established brands decline), or (b) a lower discount rate (governance clears up, refinancing succeeds at reasonable terms).
Method 3: Sum of Parts
| Segment | Revenue | Valuation Basis | Estimated Value |
|---|---|---|---|
| Nexplanon | $921M | 4x revenue (patent risk) | $3.7B |
| Fertility | $365M | 3x revenue (stable) | $1.1B |
| Other Women’s Health | $465M | 1.5x revenue | $0.7B |
| Biosimilars | $691M | 2.5x revenue (growing, shared economics) | $1.7B |
| Vtama | $128M | 6x revenue (early, high growth, patents to 2036) | $0.8B |
| Emgality | $174M | 3x revenue (distribution rights) | $0.5B |
| Other Established Brands | $3.5B | 1x revenue (declining, off-patent) | $3.5B |
| Total Enterprise Value | $12.0B | ||
| Less: Net Debt | ($8.1B) | ||
| Less: Litigation/contingencies (est.) | ($0.5B) | ||
| Equity Value | $3.4B | ||
| Per Share | $13.08 |
The sum-of-parts approach is more generous because it assigns differentiated multiples to each business line rather than a blended rate. It captures the optionality in Vtama and biosimilars that a flat EV/EBITDA multiple misses.
Scenario Summary
| Scenario | Probability | Value Per Share | Key Assumptions |
|---|---|---|---|
| Bear | 25% | $2-5 | 2028 refinancing at distressed rates, Nexplanon generic entry in 2028, SEC fine of $200M+, continued margin erosion |
| Base | 50% | $9-13 | Refinancing succeeds at 200-300bps higher, Vtama reaches $300M+ by 2028, biosimilars offset established brand decline, SEC resolves for modest amount |
| Bull | 25% | $16-22 | Strategic acquirer emerges, Vtama becomes a blockbuster, Nexplanon exclusivity holds through 2030, rapid deleveraging |
Probability-weighted expected value: $9-12 per share.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Permanent CEO announcement | Signals strategic direction and market confidence | Expected H1 2026 |
| Strategic identity under new CEO | Whether the next CEO recommits to women’s health as the primary investment filter or formalizes the broader acquire-and-distribute model. | Post-CEO appointment |
| Vtama atopic dermatitis commercial ramp | FDA approved Dec 2024; tracking uptake in the second indication will show whether the $1.2B Dermavant acquisition pays off | Quarterly earnings through 2026 |
| 2028 debt refinancing activity | The existential question for equity holders | Late 2027 / Early 2028 |
| SEC investigation resolution | Removes governance overhang and clarifies financial impact | Unknown, likely 2026-2027 |
| Xiromed/Nexplanon patent litigation ruling | Determines timeline and scope of generic competition | Mid-2027 (30-month stay expiry) |
| Hadlima and Bildyos market share trajectory | Proves out the biosimilar growth engine | Quarterly earnings |
| Vtama international launch updates | Tests whether Organon’s distribution machine can replicate US success globally | H2 2026 |
| FY2026 Q1 earnings | First quarter under new guidance, signals whether flat revenue/EBITDA is achievable | Late April / Early May 2026 |
Sources:
- 10-K filed February 24, 2026
- 10-K filed February 28, 2025 (FY2024)
- 8-K filed February 12, 2026 (Q4 2025 earnings)
- 8-K filed February 20, 2026 (Audit committee review)
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.